- Tabernero, J., Van Cutsem, E., Yoshino, T., Yaeger, R., Wasan, H., Desai, J., . . . Kopetz, S. (2023). Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E plus C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis. Annals of Oncology, 34, S174-S174. https://doi.org/10.1016/j.annonc.2023.04.501
Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E plus C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
on 30 d'octubre de 2023
with No hi ha comentaris
Deixa un comentari